Fibroids are common. Cancer of the uterus that masquerades as a fibroid is rare. But because the very rare scenario, uterine sarcoma, carries serious consequences, every gynaecologist managing fibroids is mentally running a quiet differential diagnosis: is this a benign fibroid (which it almost certainly is) or is it something that needs a different approach?
This article explains the features that distinguish fibroids from uterine sarcoma, the imaging that helps, and why the question matters even though the answer is almost always reassuring.
How common is each
Uterine fibroids (leiomyomas) affect a substantial percentage of Indian women, estimates range from 20% to 70% depending on age and how thoroughly imaging is done. They are the most common solid pelvic tumour in women, and the vast majority cause either no symptoms or symptoms that can be managed without major intervention.
Uterine sarcoma, cancer arising from the smooth muscle or connective tissue of the uterus, is uncommon, accounting for approximately 3–7% of all uterine cancers. The most common type is leiomyosarcoma; less common types include endometrial stromal sarcoma and undifferentiated sarcoma. In absolute terms, sarcoma is rare.
The challenge is that sarcoma can be mistaken for a fibroid, particularly in its early stages, because both present as a uterine mass. Distinguishing them pre-operatively is one of the harder problems in gynaecological surgery.
The features that should raise concern
A fibroid that has any of these features deserves closer evaluation rather than routine fibroid management:
Rapid growth, a fibroid that has grown materially over 3–6 months, particularly in a postmenopausal woman where fibroids typically shrink rather than grow.
Postmenopausal new presentation, a uterine mass first appearing after menopause is statistically more concerning than the same mass in a premenopausal woman.
Unusual imaging features, irregular borders, heterogeneous internal appearance, areas of necrosis (tissue death), absent or unusual blood flow patterns on Doppler imaging, MRI features suggestive of high cellularity.
Associated symptoms inconsistent with simple fibroids, unexplained weight loss, persistent constitutional symptoms, ascites, pelvic adenopathy.
Pre-procedure imaging suggesting myxoid features or central necrosis on MRI, these can be sarcoma markers.
The single most reliable way to distinguish uterine fibroids from sarcoma pre-operatively is pelvic MRI. The accuracy of MRI in this differentiation, particularly with diffusion-weighted imaging and dynamic contrast enhancement, is materially higher than ultrasound alone.
If your fibroid has any of the features above, an MRI is the standard next step, not just another ultrasound.
The fragmentation problem and morcellation
There is a specific surgical issue that has changed practice over the last decade. Traditional laparoscopic fibroid surgery often involved fragmenting (morcellating) the fibroid inside the abdomen so it could be removed through small incisions. This works well for benign fibroids, but if the mass turns out to be a sarcoma, morcellation can scatter cancer cells throughout the abdomen, worsening the prognosis substantially.
The 2014 FDA safety communication on this issue and subsequent international guidelines have led to a shift away from unprotected morcellation. Current best practice:
- Pre-operative MRI for any fibroid with concerning features, particularly in women over 40
- Endometrial biopsy before fibroid surgery if there is abnormal bleeding
- Contained morcellation within a specimen bag if morcellation is used
- Open or robotic in-bag morcellation for cases where the differential is uncertain
- Avoid power morcellation entirely in postmenopausal women
These precautions don’t eliminate the risk of an unsuspected sarcoma, but they substantially reduce the consequences when one is found incidentally.
The realistic conversation
For most Indian women with a fibroid diagnosis, the realistic picture is:
- The mass is almost certainly a benign fibroid
- Standard treatment options (observation, medical management, myomectomy, hysterectomy) all apply
- Routine pre-operative imaging is adequate
- Sarcoma is rare and the surgery is planned with that small probability in mind
For the small minority where features are concerning, the conversation shifts:
- MRI rather than just ultrasound
- Surgical planning for a possible cancer operation
- Removal of the specimen intact (no morcellation) or with strict containment
- A gynaecological oncosurgeon involved either as the primary surgeon or available intra-operatively
The point of the careful evaluation is not to assume cancer. It is to ensure that the small probability is identified and managed appropriately, so the surgical approach is right the first time.
When to seek a gynaecological oncologist
A fibroid evaluation by a gynaec oncologist is appropriate when:
- The fibroid has any of the concerning features described above
- Rapid growth has been observed over recent months, particularly post-menopause
- MRI features are atypical or worrying
- Family history suggests Lynch syndrome or other cancer predisposition
- You have a history of pelvic radiation (sarcoma risk)
- A previous fibroid surgery has shown unexpected pathology
- Tamoxifen use is in the picture
- The surgeon planning the operation does not have experience with gynaecological cancer surgery as a backup
In these scenarios, the surgical planning is different, and starting with the right specialist saves both time and avoidable surgical re-do.
What to ask before fibroid surgery
A few specific questions worth asking:
- Has an MRI been done, and what did it show?
- Have any of the imaging features raised concern about sarcoma?
- If morcellation is planned, will it be in-bag (contained) or open?
- What is the plan if intra-operative findings or frozen-section pathology suggests something other than fibroid?
- Is a gynaecological oncosurgeon available intra-operatively if needed?
These questions are reasonable and routine for any competent fibroid surgery programme.
The bottom line
Uterine fibroids are common, benign, and well-treated. Uterine sarcoma is rare but serious, and pre-operative differentiation from a fibroid is one of gynaecology’s harder problems. The features that should trigger more careful evaluation, rapid growth, postmenopausal new presentation, unusual imaging features, atypical MRI findings, are well-defined and not subtle.
For women with concerning features, MRI is the right next investigation and a sub-speciality opinion is the right next consultation. For women without concerning features, standard fibroid management, observation, medical management, or routine surgery with current safety practices, is entirely appropriate.
The goal is not anxiety. It is calibrated investigation, so the rare-but-important cases are caught and managed correctly.
About the author
This article was reviewed by Dr. Nishtha Tripathi Patel (MBBS, DGO, DNB, Fellowship in Gynaecological Oncology, ESGO-certified), an ESGO-certified gynaecological oncosurgeon in Ahmedabad who manages complex uterine masses where the differential includes both fibroids and uterine sarcoma. Reach her practice at +91 76988 00333.
Comments are closed.